Complement Terminal Pathway Activation and Intrarenal Immune Response in C3 Glomerulopathy
Marie-Sophie Meuleman(Inserm), Sophie Chauvet(Assistance Publique – Hôpitaux de Paris), Florent Petitprez(Inserm), Anne Grünenwald(Université Paris Cité), Anissa Moktefi(Inserm), Alexandre Karras(Délégation Paris 5), Véronique Frémeaux‐Bacchi(Assistance Publique – Hôpitaux de Paris), Viviane Gnemmi(Université Paris-Saclay), Alyssa Gilmore(Centre for Inflammation Research), Aude Servais(Hôpital Necker-Enfants Malades), Julien Hogan(Assistance Publique – Hôpitaux de Paris), Moglie Le Quintrec(Centre de Recherche des Cordeliers), Lubka T. Roumenina(Université Paris Cité), Maëva Eloudzeri(Centre National de la Recherche Scientifique), Marion Rabant(Hôpital Necker-Enfants Malades), David Buob(Inserm), Jean‐Jacques Boffa(Sorbonne Université), Vincent Audard(Inserm), Olivia Boyer(Hôpital Necker-Enfants Malades), Frank Bridoux(Université de Poitiers), Mikel Rezola Artero(Inserm), Matthew C. Pickering(Imperial Valley College), Éric Thervet(Délégation Paris 5), François Provôt(Centre Oscar Lambret), Jean–Paul Duong Van Huyen(Hôpital Necker-Enfants Malades), Jean‐Michel Goujon(Centre Hospitalier Universitaire de Poitiers), Anna Duval(Inserm)
Cited by 11
Related Papers
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases
|Kidney International|2021|2.5k
Complement System Part I – Molecular Mechanisms of Activation and Regulation
|Frontiers in Immunology|2015|1.5k
The Banff 2019 Kidney Meeting Report (I): Updates on and clarification of criteria for T cell– and antibody-mediated rejection
|American Journal of Transplantation|2020|809
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases
|Kidney International|2021|809